A detailed history of Meeder Asset Management Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Meeder Asset Management Inc holds 31,672 shares of BMY stock, worth $1.83 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
31,672
Previous 16,343 93.8%
Holding current value
$1.83 Million
Previous $678,000 141.74%
% of portfolio
0.11%
Previous 0.05%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$39.66 - $51.75 $607,948 - $793,275
15,329 Added 93.8%
31,672 $1.64 Million
Q2 2024

Aug 08, 2024

SELL
$40.25 - $52.99 $4.57 Million - $6.01 Million
-113,460 Reduced 87.41%
16,343 $678,000
Q1 2024

May 07, 2024

BUY
$47.98 - $54.4 $3.09 Million - $3.51 Million
64,433 Added 98.57%
129,803 $7.04 Million
Q4 2023

Jan 25, 2024

BUY
$48.48 - $57.85 $2.91 Million - $3.48 Million
60,122 Added 1145.62%
65,370 $3.35 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $3.38 Million - $3.78 Million
-58,369 Reduced 91.75%
5,248 $304,000
Q2 2023

Aug 11, 2023

BUY
$63.71 - $70.74 $24,082 - $26,739
378 Added 0.6%
63,617 $4.07 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $673,067 - $763,410
10,243 Added 19.33%
63,239 $4.38 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $4.4 Million - $5.21 Million
-64,245 Reduced 54.8%
52,996 $3.81 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $2,587 - $1.53 Million
-19,900 Reduced 14.51%
117,241 $8.34 Million
Q2 2022

Aug 08, 2022

BUY
$72.62 - $79.98 $534,701 - $588,892
7,363 Added 5.67%
137,141 $10.6 Million
Q1 2022

May 10, 2022

BUY
$61.48 - $73.72 $6.76 Million - $8.11 Million
109,969 Added 555.15%
129,778 $9.48 Million
Q4 2021

Feb 11, 2022

SELL
$53.63 - $62.52 $8.58 Million - $10 Million
-160,000 Reduced 88.98%
19,809 $1.24 Million
Q3 2021

Nov 08, 2021

BUY
$59.17 - $69.31 $77,808 - $91,142
1,315 Added 0.74%
179,809 $10.6 Million
Q2 2021

Aug 09, 2021

BUY
$61.91 - $67.42 $2.04 Million - $2.23 Million
33,015 Added 22.69%
178,494 $11.9 Million
Q1 2021

Apr 28, 2021

BUY
$59.34 - $66.74 $7.67 Million - $8.63 Million
129,320 Added 800.3%
145,479 $9.18 Million
Q4 2020

Feb 09, 2021

SELL
$57.74 - $65.43 $7.35 Million - $8.33 Million
-127,335 Reduced 88.74%
16,159 $1 Million
Q3 2020

Nov 02, 2020

BUY
$57.43 - $63.64 $252,232 - $279,506
4,392 Added 3.16%
143,494 $8.65 Million
Q2 2020

Aug 11, 2020

BUY
$54.82 - $64.09 $433,242 - $506,503
7,903 Added 6.02%
139,102 $8.18 Million
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $166,019 - $241,264
3,578 Added 2.8%
131,199 $7.31 Million
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $5.67 Million - $7.39 Million
115,165 Added 924.57%
127,621 $8.19 Million
Q3 2019

Oct 17, 2019

SELL
$42.77 - $50.71 $1.75 Million - $2.07 Million
-40,837 Reduced 76.63%
12,456 $631,000
Q2 2019

Aug 05, 2019

SELL
$44.62 - $49.34 $830,735 - $918,612
-18,618 Reduced 25.89%
53,293 $2.42 Million
Q1 2019

Apr 16, 2019

BUY
$45.12 - $53.8 $36,817 - $43,900
816 Added 1.15%
71,911 $3.43 Million
Q4 2018

Jan 17, 2019

BUY
$48.76 - $63.23 $1.24 Million - $1.61 Million
25,449 Added 55.75%
71,095 $3.7 Million
Q3 2018

Nov 02, 2018

BUY
$55.19 - $62.25 $1.07 Million - $1.2 Million
19,346 Added 73.56%
45,646 $0
Q2 2018

Jul 24, 2018

SELL
$50.53 - $62.98 $2.67 Million - $3.33 Million
-52,902 Reduced 66.79%
26,300 $0
Q1 2018

May 03, 2018

BUY
$59.92 - $68.98 $1.18 Million - $1.36 Million
19,699 Added 33.11%
79,202 $5.01 Million
Q4 2017

Feb 02, 2018

BUY
$59.94 - $65.35 $2.97 Million - $3.24 Million
49,550 Added 497.84%
59,503 $3.65 Million
Q3 2017

Oct 20, 2017

BUY
$55.23 - $63.74 $549,704 - $634,404
9,953
9,953 $635,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.